Close Menu

NEW YORK – Promega said on Thursday that it has signed a license agreement for MilliporeSigma's foundational CRISPR genome editing technology.

Under the terms of the agreement, Promega will use the CRISPR technology to create new research products for investigating endogenous biology, including products for drug development. The company is aiming to develop tools that will allow researchers to better determine physiological levels of protein expression, providing a more accurate understanding of protein behavior.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.